Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement.
Christine E RyanRebecca L ZonRobert ReddDavid C FisherRoni ShouvalAnita KumarJennifer L CrombieHossein SadrzadehAustin I KimLakshmi NayakUgonma N ChukwuekeCaron A JacobsonMatthew J FrigaultM Lia PalombaPhilippe ArmandZachary D Epstein-PetersonReid W MerrymanPublished in: British journal of haematology (2023)
Data describing outcomes of chimeric antigen receptor (CAR) T-cell therapy in patients with secondary central nervous system (SCNS) involvement of mantle cell lymphoma (MCL) are limited. We identified 10 patients with MCL and SCNS involvement treated with anti-CD19 CAR T-cell therapy at three US academic centres. Frequent objective responses were observed in the CNS (86%) and systemically (90%), and the 1-year progression-free survival was 47%. Seven patients developed immune-effector-cell-associated-neurotoxicity-syndrome (n = 2 Grade 1, n = 5 Grade 3). Our results suggest that anti-CD19 CAR T-cell therapy in this setting is feasible and additional data regarding neurotoxicity in this population may be warranted.
Keyphrases
- cell therapy
- free survival
- stem cells
- mesenchymal stem cells
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- big data
- cerebrospinal fluid
- prognostic factors
- immune response
- type diabetes
- nk cells
- patient reported outcomes
- bone marrow
- metabolic syndrome
- single cell
- artificial intelligence
- patient reported
- machine learning